Fractionated radiotherapy and chemotherapy with an oxygen therapeutic
Inventors
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-10946097-B2
Publication Date
2021-03-16
Expiration Date
Abstract
A fluorocarbon emulsion in water for use in fractionated radiotherapy and chemotherapy, wherein said fluorocarbon comprises between 4 and 8 carbon atoms.
Core Innovation
The invention describes a method of treating glioblastoma by multi-fraction radiotherapy or chemotherapy using a water emulsion of perfluoropentane. The method administers the perfluoropentane emulsion concomitantly or up to 120 minutes prior to each fraction of radiation therapy, or concomitantly with chemotherapy.
The method further includes simultaneously administering carbogen or supplemental oxygen to the subject. This approach is presented as a radiosensitizer strategy in which tumor re-oxygenation is used to overcome hypoxia during fractionated radiotherapy.
The document describes formulation and design features for the emulsion, including the presence of a viscosity modifier and a fluorosurfactant, with examples such as sucrose as a viscosity modifier and fluorosurfactants such as PEG Telomer B. It also describes additional formulation options, including phospholipid surfactants and optional buffers.
Claims Coverage
The partial content includes one independent claim (clm-00001). The independent claim defines a multi-fraction radiotherapy or chemotherapy treatment of glioblastoma using a perfluoropentane water emulsion with specified composition constraints, a specified dosage range, a defined administration timing window relative to each radiation fraction, and simultaneous carbogen or supplemental oxygen delivery.
Glioblastoma multi-fraction radiotherapy or chemotherapy with perfluoropentane emulsion
A method of treating glioblastoma by multi-fraction radiotherapy or chemotherapy comprising administering a water emulsion of perfluoropentane concomitantly or up to 120 minutes prior to each fraction of radiation therapy, or concomitantly with chemotherapy.
Perfluoropentane emulsion composition with viscosity modifier and fluorosurfactant at 1% to 5% w/vol
The perfluoropentane emulsion comprises a viscosity modifier, a fluorosurfactant, and about 1% to 5% w/vol of perfluoropentane.
Perfluoropentane emulsion dosage range
The perfluoropentane emulsion is administered at a dosage in the range from about 0.05 cc/kg to about 0.3 cc/kg.
Simultaneous carbogen or supplemental oxygen administration
Simultaneously administering carbogen or supplemental oxygen.
Across the independent claim, the main inventive elements are the glioblastoma treatment method that combines multi-fraction radiotherapy or chemotherapy with timed administration of a perfluoropentane water emulsion at about 0.05 to 0.3 cc/kg, together with simultaneous carbogen or supplemental oxygen.
Stated Advantages
Not explicitly described in patent.
Documented Applications
Fractionated radiotherapy and/or chemotherapy oncology context in glioblastoma, including example glioblastoma treatment with perfluoropentane emulsion given before each radiation fraction with temozolomide.
A xenograft oncology context involving Hs-766T pancreatic cancer xenografts, used to discuss oxygenation and tumor growth rationale.
Interested in licensing this patent?